Open Access

Proteomic patterns of cervical cancer cell lines, a network perspective

  • Juan Carlos Higareda-Almaraz1,
  • María delRocío Enríquez-Gasca1, 2,
  • Magdalena Hernández-Ortiz1,
  • Osbaldo Resendis-Antonio1 and
  • Sergio Encarnación-Guevara1Email author
Contributed equally
BMC Systems Biology20115:96

DOI: 10.1186/1752-0509-5-96

Received: 4 February 2011

Accepted: 22 June 2011

Published: 22 June 2011

Abstract

Background

Cervical cancer is a major mortality factor in the female population. This neoplastic is an excellent model for studying the mechanisms involved in cancer maintenance, because the Human Papilloma Virus (HPV) is the etiology factor in most cases. With the purpose of characterizing the effects of malignant transformation in cellular activity, proteomic studies constitute a reliable way to monitor the biological alterations induced by this disease. In this contextual scheme, a systemic description that enables the identification of the common events between cell lines of different origins, is required to distinguish the essence of carcinogenesis.

Results

With this study, we sought to achieve a systemic perspective of the common proteomic profile of six cervical cancer cell lines, both positive and negative for HPV, and which differ from the profile corresponding to the non-tumourgenic cell line, HaCaT. Our objectives were to identify common cellular events participating in cancer maintenance, as well as the establishment of a pipeline to work with proteomic-derived results. We analyzed by means of 2D SDS-PAGE and MALDI-TOF mass spectrometry the protein extracts of six cervical cancer cell lines, from which we identified a consensus of 66 proteins. We call this group of proteins, the "central core of cervical cancer". Starting from this core set of proteins, we acquired a PPI network that pointed, through topological analysis, to some proteins that may well be playing a central role in the neoplastic process, such as 14-3-3ζ. In silico overrepresentation analysis of transcription factors pointed to the overexpression of c-Myc, Max and E2F1 as key transcription factors involved in orchestrating the neoplastic phenotype.

Conclusions

Our findings show that there is a "central core of cervical cancer" protein expression pattern, and suggest that 14-3-3ζ is key to determine if the cell proliferates or dies. In addition, our bioinformatics analysis suggests that the neoplastic phenotype is governed by a non-canonical regulatory pathway.

Background

The definition of cancer has evolved according to the knowledge and perspective of the scientific context in which it is conceived. It has changed from a highly heterogeneous disease seen from a cell type and tissue of origin point of view, to the conception of cancer as an illness that involves the deregulation of various pathways that govern key, and somewhat common, cellular processes [1]. Particularly, in 2000 Hanahan and Weinberg suggested that all cancer types represent a manifestation of six essential alterations in cell physiology that collectively coordinate the malignant phenotype: self-sufficiency in growth signals, insensitivity to growth inhibitors, evasion of programmed cell death, increase of the replicative potential, sustained angiogenesis and tissue invasion and metastasis [2]. Furthermore, in a recent review published by the same two authors, they proposed two emerging hallmarks: reprogramming of energy metabolism and evading immune destruction; besides suggesting genomic instability and mutations, as well as tumor-promoting inflammation, as enabling characteristics [3].

Regardless of the latter, several cancer types have been more intensively studied due to their penetrance in the human population, such as prostate and breast cancer. However, we see in cervical cancer a unique opportunity to study the malignant transformation because of its common origin: 90.7% of the cases arise as a consequence of High-Risk Human Papilloma Virus (HR-HPV) infection, according to a study carried out in nine countries of diverse cervical cancer incidences [4]. HR-HPVs encode the E6 and E7 oncoproteins, which interact with the well known and very common, tumor suppressor proteins p53 and pRB, respectively; among several other proteins that together impart a very strong oncogenic potential to the virus [57].

To date 120 types of human papillomaviruses have been identified, which can be subdivided into low-risk types, found mainly in genital warts, and high-risk types, which are frequently associated with invasive cervical cancer [8]. Among the high-risk types HPV16 and HPV18 are the most prevalent, present in 54.6% and 11% of squamous cervical carcinomas, respectively [4]. This is part of the reason why, cervical cancers derived from patients infected with those viral types, have been intensively studied, and one of the best studied human cell line, HeLa, is positive for HPV18 [9]. Likewise, it is pertinent to mention that there are other cell lines which originated from HPV negative cervical cancers that have also been widely studied and therefore, enable the visualization of alterations in protein expression, common to many cervical cancer cell lines independently of their origin.

Cervical cancer is one of the most common types of cancer and a major mortality factor of women worldwide [4]. Because most of the cases are a consequence of viral infections, cervical cancer is a disease that has been successfully addressed in developed countries thanks to preventive medicine [10]. Nonetheless, when left unattended, a persistent viral infection combined with a strong and constitutive expression of viral oncoproteins E6 and E7 are highly inductive steps towards the malignant transformation of cervical epithelium [5]. However, owing to a frequent and spontaneous elimination of viral sequences, not all the patients infected with HR-HPV develop cervical cancer [11]. This indicates that most HPV infections are subclinical and only a small fraction of HR-HPV infections produce early epithelial lesions, and a more modest fraction of those lesions will develop into cancer. Consequently, even if infection by HR-HPV can be considered as the initial hit that gives rise to cervical cancer, the superseding steps that enable cancer development have not yet been described [12].

Currently, an accurate prediction of the evolution of the tumor is one of the biggest challenges for clinical oncology. Because of this, the conception of an integrative model that enables the prediction of future states of a system has become of vital importance. We consider that one of the best approaches currently available to accomplish this task are protein-protein interactions (PPI), because they encompass the scaffold of molecular pathways and cellular processes, besides being capable of revealing the dynamic and interactive function of human proteins [13]. Furthermore, available databases of some organisms have promoted the construction of networks which become the starting point to explore and infer the fundamental principles by which the cell orchestrates its response to different kinds of perturbations.

In this work, we developed a pipeline for the functional analysis of differentially expressed proteins in cervical cancer compared with a non-cancerous control and obtained from 2D SDS-PAGE. We used PPI networks, pathways and GOs enrichment analysis, succeeded by an analysis of the promoter gene sequences to get a more systemic point of view of cervical cancer. We consider that the main advantage of following this approach is that it enabled to explore and locate important proteins for the biological phenomenon, which could have been overlooked as a consequence of the experimental methodology used, because some proteins are present in low concentrations or posses isoelectric points or molecular weights located outside the electrophoretic resolution range utilized in 2D SDS-PAGE.

Results

A conserved protein expression pattern exists in cervical cancer cell lines

Protein extracts of the six cancer cell lines: two cell lines which are positive for infection with HPV type 18 (HeLa and CaLo), two positive for HPV type 16 (SiHa and CasKi), and two HPV negative (ViBo and C-33A); and HaCaT, a spontaneously immortalized keratinocyte cell line we used as control, were obtained and analyzed by 2D SDS-PAGE (Figure 1). In our opinion, this experimental design permitted the identification of proteins that are common to the neoplastic phenotype regardless of the presence of intrinsic variations, such as a virus. We set the HaCaT cell line as a control because it is of epithelial origin and has an extended replicative potential, which allows us to distinguish between the biological events of transformation and immortality. Also, it has been widely used as a control in several studies of cervical cancer [14].
https://static-content.springer.com/image/art%3A10.1186%2F1752-0509-5-96/MediaObjects/12918_2011_Article_714_Fig1_HTML.jpg
Figure 1

Pipeline. We compared the protein profiles of six cervical cancer cell lines by 2D SDS-PAGE, and established a set of proteins common to these cell lines, and which did not feature in our control. This set of proteins was termed "central core of cervical cancer", (a). From the central core, we reconstructed a PPI network (b), this network expanded and used to obtain the overrepresented GO's and pathways. Finally, we conducted an analysis of the transcription factors contained in the extended network using ChIP-Seq analysis of the ENCODE project (c).

Three independent analyses were performed and used for protein profiling. For each sample, 2-D gel electrophoresis was carried out in a pH range of 3 to 10. The Coomassie-stained gels were acquired with densitometer GS-800 (Bio-Rad) and analyzed using PD-Quest software v 8.0.1. On average, more than 1,000 protein spots were revealed in each 2-DE gel. The quantity of each spot in a gel was normalized as a percentage of the total quantity in the map, according to its optical density (OD) value. We focused on the electrophoretic entities which were present in all six cancer cell lines but did not appear in the HaCaT control, or those which changed consistently and significantly (more than 2-fold). We call this group of 127 proteins, the "central core of cervical cancer". Among the 127 spots analyzed, 98 proteins were identified based on their tryptic peptide masses using the MALDI-TOF equipment, resulting in 66 unique proteins. (Table 1).
Table 1

Proteins identified as members of the "central core of cervical cancer".

Accession number

Name

Score

Expect

Searched-Matched

Coverage

GRP78_HUMAN

78 kDa glucose-regulated protein

391

1.60E-035

91 - 46

58%

ENOA_HUMAN

Alpha-enolase

327

4.00E-029

82 - 34

82%

GRP78_HUMAN

79 kDa glucose-regulated protein

302

1.30E-026

64 - 32

47%

HSP7C_HUMAN

Heat shock cognate 71 kDa protein

294

8.10E-026

70 - 39

48%

VIME_HUMAN

Vimentin

290

2.00E-025

64 - 33

63%

ENOA_HUMAN

Alpha-enolase

286

5.10E-025

82 - 34

82%

PDIA1_HUMAN

Protein disulfide-isomerase

252

1.30E-021

77 - 30

55%

ANXA2_HUMAN

Annexin A2

249

2.60E-021

65 - 31

72%

TBB5_HUMAN

Tubulin beta chain

247

4.00E-021

73 - 32

62%

ANXA4_HUMAN

Annexin A4

233

1.00E-019

50 - 25

59%

EFTU_HUMAN

Elongation factor Tu, mitochondrial

217

4.00E-018

44 - 22

52%

TPIS_HUMAN

Triosephosphate isomerase

206

5.10E-017

42 - 17

69%

VIME_HUMAN

Vimentin

206

5.10E-017

62 - 23

50%

PGAM1_HUMAN

Phosphoglycerate mutase 1

205

2.10E-016

41 - 18

58%

ATPB_HUMAN

ATP synthase subunit beta, mitochondrial

193

1.00E-015

84 - 44

72%

ACTG_HUMAN

Actin, cytoplasmic 2

192

1.30E-014

50 - 20

48%

PUR9_HUMAN

Bifunctional purine biosynthesis protein PURH

191

1.60E-015

49 - 22

45%

KCRB_HUMAN

Creatine kinase B-type

178

3.20E-014

50 - 19

48%

EF2_HUMAN

Elongation factor 2

154

8.10E-012

67 - 26

33%

HYOU1_HUMAN

Hypoxia up-regulated protein 1

154

8.10E-012

38 - 19

22%

KCRB_HUMAN

Creatine kinase B-type

154

8.10E-012

50 - 19

48%

PPIA_HUMAN

Peptidyl-prolyl cis-trans isomerase A

150

2.00E-011

45 - 16

81%

GELS_HUMAN

Gelsolin

147

4.00E-011

46 - 19

30%

VINC_HUMAN

Vinculin

145

6.40E-011

36-19

20%

WDR1_HUMAN

WD repeat-containing protein 1

144

8.10E-011

46 - 16

31%

EZRI_HUMAN

Ezrin

131

1.60E-009

60 - 26

34%

HSP71_HUMAN

Heat shock 70 kDa protein 1A/1B

129

2.60E-009

42 - 21

33%

TBA1C_HUMAN

Tubulin alpha-1C chain

127

4.00E-009

45 - 13

37%

PRDX1_HUMAN

Peroxiredoxin-1

126

5.10E-009

53 - 18

58%

PDIA3_HUMAN

Protein disulfide-isomerase A3

125

6.40E-009

47 - 15

28%

GRP75_HUMAN

Stress-70 protein, mitochondrial

123

1.00E-008

81 - 34

43%

DHSA_HUMAN

Succinate dehydrogenase flavoprotein subunit

122

3.30E-007

39 - 17

21%

RSSA_HUMAN

40S ribosomal protein SA

121

1.60E-008

37 - 11

34%

HS90B_HUMAN

Heat shock protein HSP 90-beta

119

2.6e-08

44 - 19

27%

ESTD_HUMAN

S-formylglutathione hydrolase

114

8.10E-008

25 - 11

41%

TKT_HUMAN

Transketolase

114

8.10E-008

52 - 19

32%

LDHB_HUMAN

L-lactate dehydrogenase B chain

112

1.30E-007

43 - 20

36%

AL1A1_HUMAN

Retinal dehydrogenase 1

110

2.00E-007

58 - 19

34%

IPYR_HUMAN

Inorganic pyrophosphatase

110

2.00E-007

22 - 9

35%

DDX3X_HUMAN

ATP-dependent RNA helicase DDX3X

108

3.20E-007

23 - 13

20%

DHE3_HUMAN

Glutamate dehydrogenase 1, mitochondrial

107

4.00E-007

38 - 13

29%

G3P_HUMAN

Glyceraldehyde-3-phosphate dehydrogenase

107

4.00E-007

55 - 13

42%

ACON_HUMAN

Aconitate hydratase, mitochondrial

105

6.40E-007

54 - 23

30%

ML12A_HUMAN

Myosin regulatory light chain 12A

105

6.40E-007

32 - 11

63%

RIR1_HUMAN

Ribonucleoside-diphosphate reductase large subunit

101

1.60E-006

28 - 15

18%

EF2_HUMAN

Elongation factor 2

99

2.60E-006

60-20

29%

QCR1_HUMAN

Cytochrome b-c1 complex subunit 1, mitochondrial

98

3.30E-006

45 - 15

29%

CNN2_HUMAN

Calponin-2

96

4.50E-006

51 - 13

48%

PCBP1_HUMAN

Poly(rC)-binding protein 1

94

8.30E-006

39 - 14

44%

IMMT_HUMAN

Mitochondrial inner membrane protein

92

1.30E-005

34 - 13

20%

CAPG_HUMAN

Macrophage capping protein

91

1.80E-005

41 - 11

30%

TCTP_HUMAN

Translationally-controlled tumor protein

91

1.80E-005

19 - 8

40%

PSB4_HUMAN

Proteasome subunit beta type-4

89

1.70E-003

20 - 7

34%

TERA_HUMAN

Transitional endoplasmic reticulum ATPase

88

3.10E-005

49 - 15

21%

K2C1_HUMAN

Keratin, type II cytoskeletal 1

87

3.70E-005

46 - 13

29%

LEG1_HUMAN

Galectin-1

84

7.70E-005

41 - 8

51%

1433Z_HUMAN

14-3-3 protein zeta/delta

80

2.30E-004

43 - 14

54%

LMNA_HUMAN

Prelamin-A/C

78

3.40E-004

37 - 11

22%

HNRPL_HUMAN

Heterogeneous nuclear ribonucleoprotein L

77

4.10E-004

27 - 13

16%

TCPH_HUMAN

T-complex protein 1 subunit eta

77

4.00E-004

36 - 15

30%

OSBL8_HUMAN

Oxysterol-binding protein-related protein 8

73

1.10E-003

56 - 13

21%

TCPE_HUMAN

T-complex protein 1 subunit epsilon

71

1.70E-003

30 - 11

23%

HYOU1_HUMAN

Hypoxia up-regulated protein 1

70

2.20E-003

28 - 13

14%

PSA5_HUMAN

Proteasome subunit alpha type-5

69

2.70E-003

17 - 6

25%

FOXP3_HUMAN

Forkhead box protein P3

68

3.40E-003

41 - 12

34%

The entry name corresponds to the UniProt database, the score and expect value were obtained from the search engine Mascot. The expect value is the number of matches with equal or better scores that are expected to occur by chance alone. Score as -10*LOG10(P), where P is the absolute probability. The lower the expectation value, the more significant the score.

Since this study pointed to a "central core of cervical cancer", it was necessary to understand the nature of the proteins involved in the process. To this end, 66 proteins were classified via GO (Gene Ontology) using QuickGo of EMBL-EBI database [15]. The identities of the proteins of the central core confirm that these are important in cancer because several studies have linked their aberrant expression to the neoplastic phenotype. With reference to their assigned functions, these proteins can be divided into at least three groups:

The first group includes proteins related to cell migration and metastasis, like anexin 2 that plays a crucial role in establishing metastasis of prostate cancer (PCa) by regulating the adhesion and migration of PCa to osteoblasts and endothelial cells [16]; protein disulfide-isomerase which is strongly expressed by invasive glioma cells, and its inhibition led to reduced glioma cell migration and invasion [17]; vimentin, an intermediate filament cytoskeletal protein and a marker of Epithelial Mesenchymal Transition (EMT), contributes to invasion and metastasis in prostate cancer [18]; ezrin is required for invasion and metastasis of mammary carcinoma [19]; and finally vinculin, which facilitates contractile force generation, enhancing cell invasion [20]. This group of proteins could be a sign of invasion and metastasis in cervical cancer, similar to their role in other cancer types.

In a second group, we placed proteins related to evasion of apoptosis: GRP78, HSP71, HSP7C, HS90B and GRP75. These proteins are activated as part of the Unfolded Proteins Response (UPR), which has been largely related to survival, cell proliferation and angiogenesis [21]. Likewise, it has been shown that overexpression of GRP78 is sufficient to confer apoptosis resistance in at least two cell types, regardless of its function within the UPR [22]. We believe these proteins could be a link between different hallmarks of cancer, like apoptosis evasion, angiogenesis and proliferation.

In a third group, we find proteins involved in or associated with central metabolism like glyceraldehyde 3 phosphate dehydrogenase, phosphoglycerate mutase 1, enolase A, triosephosphate isomerase and L-lactate dehydrogenase B. We consider that the expression of this group of proteins could be due to the cancerous cells' need to divide their incoming nutrients between energy production and macromolecular biosynthesis to support cell growth and DNA replication. This increase in cell metabolism has been described in cancer cells, which exhibit a much higher intake of glucose than normal cells, as well as increased rates of glycolysis and lactate production even in the presence of oxygen [2326].

Another protein detected by us as a member of the "central core of cervical cancer" was galectin-1. Remarkably, very recently it was reported that cells can stimulate tumor angiogenesis by secretion of this protein, and it was previously found in the vasculature of many human tumors, including colon, head and neck, lung, prostate, and oral cancers [27, 28]. All of the proteins identified as members of the "central core of cervical cancer" are summarized in Table 1.

14-3-3ζ is a Hub in our protein-protein interaction network

We performed a theoretical interactome (Figure 2) using the Cytoscape plugin, Bisogenet, to add the experimentally verified interactions between the 66 identified proteins. This plugin employs the SysBiomics database which integrates information from the INTACT [29], BIOGRID [30], MINT [31], DIP [32], BIND [33] and HPRD [34] databases.
https://static-content.springer.com/image/art%3A10.1186%2F1752-0509-5-96/MediaObjects/12918_2011_Article_714_Fig2_HTML.jpg
Figure 2

Network Reconstruction. Network of differentially expressed proteins in cervical cancer cell-lines compared to a non-cancerous control. The connections between proteins represent experimentally verified protein-protein interactions between 33 out of the 66 proteins identified in this study. The proteins not included in this network do not have experimentally proven interactions. The network was constructed using Cytoscape and the plugin Bisogenet.

Even though we identified 66 members of the central core of cervical cancer, we were able to integrate into a network only half of them because of a lack of experimental evidence supporting PPIs. Notably, through a topological analysis carried out on this network, we found that the 14-3-3ζ protein features as a highly interconnected node (Figure 2). Additionally, western blot analysis confirmed that all cervical cancer cell lines express high protein levels of 14-3-3ζ. In contrast, no blot of this protein was found in our control (Figure 3).
https://static-content.springer.com/image/art%3A10.1186%2F1752-0509-5-96/MediaObjects/12918_2011_Article_714_Fig3_HTML.jpg
Figure 3

Overexpression of 14-3-3ζ. The expression levels of 14-3-3ζ in the six cervical cancer cell lines were assessed by western blot analysis. Whole brain extract was used a positive control, because 14-3-3ζ has a strong expression in this tissue. α-Tubulin was used as a loading control (Data not shown).

Afterwards, we expanded the PPI network as a way to integrate all the proteins of the central core, in order to obtain a coherent output which could be related in its entirety to the neoplastic phenotype. It also served the purpose of broadening our perspective and strengthening the statistical significance of our results.

The network expansion was performed considering the experimentally obtained proteins as bait; the expansion criterion was to include proteins that have a direct experimental interaction in the databases, and were connected via a shortest path of 1 to our proteins. This resulted in a network of 1,321 nodes and 9,666 edges (Figure 4).
https://static-content.springer.com/image/art%3A10.1186%2F1752-0509-5-96/MediaObjects/12918_2011_Article_714_Fig4_HTML.jpg
Figure 4

Network Extension. Expanded network taking identified proteins as bait. Proteins belonging to our core of differentially expressed proteins were used as bait to fish protein-protein experimental interactions by adding neighbors of input nodes to a distance of up to one protein. This resulted in a network of 1,321 nodes and 9,666 edges. The network was expanded using Cytoscape and the plugin Bisogenet. Pink nodes represent the bait proteins, while the blue nodes correspond to the proteins that were included as a result of the network expansion.

We considered that the network expansion would allow us to place the entities belonging to our central core in a broader context, specially because the amount of proteins that were identified represent a small fraction of all the entities responsible for the phenotype. We also expected to observe the same topological phenomena in the expanded network as we did in the network composed solely of cervical cancer-specific proteins.

A connectivity distribution analysis allowed us to identify those proteins that highly interact with others, defined as the hubs of the expanded network. This pointed once again to the multifunctional regulator of cell signal transduction and adaptor protein, 14-3-3ζ, followed by 14-3-3γ with less than half the number of interactions. Also, we calculated the betweenness of all the proteins in the network, because it is a feature which allows us to explore the connection between local network structure and global network topology, besides representing a measure of a node's influence over information transfer [35, 36]. The proteins with the highest betweenness were 14-3-3ζ, vimentin and vinculin, part of our central core of cervical cancer proteins, which is consistent with their role as bait proteins. However, there were also non-bait nodes that featured among the proteins with highest betweenness, such as ubiquitin and 14-3-3γ; thus, supporting the notion that the betweenness metric, though biased in this case, is still a valid metric of essentiality and robustness.

The enrichment analysis of gene ontology level 3 category of biological processes shows 16 overrepresented GOs (Table 2); the enriched KEGG pathway-based analysis shows 16 significant pathways (Table 3). Although both enrichments are of great value for the analysis of the biological significance of our proteins, these have the limitation of considering the same protein or set of proteins as part of different, and sometimes unrelated, processes or pathways (Table 3). Consequently, results should be carefully assessed before making further interpretations.
Table 2

Enriched gene ontology level 3 categories of biological processes.

 

gene ontology term

set size

candidates contained

p-value

q-value

GO:0006986

response to unfolded protein

73

8

3.11E-009

7.03E-007

GO:0070841

inclusion body assembly

13

4

4.26E-007

4.82E-005

GO:0006091

generation of precursor metabolites and energy

363

11

2.02E-006

1.52E-004

GO:0032507

maintenance of protein location in cell

80

6

3.14E-006

1.77E-004

GO:0016052

carbohydrate catabolic process

132

7

4.67E-006

1.93E-004

GO:0051651

maintenance of location in cell

87

6

5.13E-006

1.93E-004

GO:0012501

programmed cell death

1338

20

7.18E-006

2.32E-004

GO:0010941

regulation of cell death

1136

18

1.06E-005

2.99E-004

GO:0046907

intracellular transport

855

15

2.08E-005

5.21E-004

GO:0002349

histamine production involved in inflammatory response

2

2

2.56E-005

5.25E-004

GO:0043455

regulation of secondary metabolic process

2

2

2.56E-005

5.25E-004

GO:0002443

leukocyte mediated immunity

184

7

4.05E-005

7.64E-004

GO:0044248

cellular catabolic process

1028

16

4.56E-005

7.92E-004

GO:0050777

negative regulation of immune response

40

4

4.91E-005

7.93E-004

GO:0070727

cellular macromolecule localization

610

12

5.29E-005

7.98E-004

GO:0051235

maintenance of location

133

6

5.79E-005

8.18E-004

Set size refers to the number of entities that have a Uniprot ID as stated in the corresponding GO category at the ConsensusPathDB site. The number of candidates contained refers to amount of proteins identified in this study that appear as part of the GO category. P-values are calculated according to a hypergeometric test; q-values represent p-values corrected for multiple testing using the false discovery rate method.

Table 3

Enriched KEGG pathway-based sets.

pathway name

set size

candidates contained

p-value

q-value

pathway source

Small cell lung cancer

84

37

8.67E-009

1.43E-006

KEGG

Protein processing in endoplasmic reticulur

164

57

4.21E-008

3.47E-006

KEGG

Pathways in cancer

325

94

8.81E-008

4.05E-006

KEGG

Apoptosis

87

36

9.82E-008

4.05E-006

KEGG

Neurotrophin signaling pathway

125

46

1.24E-007

4.10E-006

KEGG

T cell receptor signaling pathway

108

41

2.25E-007

6.19E-006

KEGG

Focal adhesion

199

62

9.45E-007

2.23E-005

KEGG

Prostate cancer

89

33

6.11E-006

1.26E-004

KEGG

Pathogenic Escherichia coli infection

54

23

1.13E-005

2.07E-004

KEGG

Endometrial cancer

52

22

1.99E-005

3.28E-004

KEGG

Shigellosis

61

24

3.61E-005

5.42E-004

KEGG

Non-small cell lung cancer

54

22

4.03E-005

5.54E-004

KEGG

Proteasome

44

19

5.17E-005

6.56E-004

KEGG

Bacterial invasion of epithelial cells

70

26

5.59E-005

6.59E-004

KEGG

B cell receptor signaling pathway

75

27

7.62E-005

8.38E-004

KEGG

Leukocyte transendothelial migration

116

37

8.27E-005

8.53E-004

KEGG

Set size refers to the number of entities that have a Uniprot ID as stated in the corresponding KEGG pathway-based set at the ConsensusPathDB site. The number of candidates contained refers to amount of proteins which are part of the extended network and appear as part of the pathway. P-values are calculated according to a hypergeometric test; q-values represent p-values corrected for multiple testing using the false discovery rate method.

There are common regulatory features among the proteins of the expanded network

Using the information generated by the ENCODE project, we searched among the transcription factors (TF) that had chromatin immunoprecipitation-sequencing (ChIP-Seq) data available, for overrepresented binding sites of a given TF in the genes of our expanded network (Figure 1). We evaluated for enrichment by considering binding sites that were located up to 700 bp upstream or 300 bp downstream of all the transcription start sites reported in the GENCODE database and that had a score larger than 750. We considered these 1,000 bp as the promoter sequence, because it has been reported to be the region of highest ChIP-Seq peak concentration in previous studies [37].

For the promoters of genes that belong to our expanded network, we focused again on the information provided in GENCODE. Out of the 1,321 nodes in the network we retrieved 1,431 promoters corresponding to 957 unique genes of the network. We found that the transcription factors E2F1 (p-value of 4.81E-13], TCF4 (p-value of 1.46E-12], c-Myc (p-value of 5.52E-11), Max (p-value of 9.77E-11), E2F6 (p-value of 1.17E-10) and NFKB (p-value of 5.02E-10) were the most significantly overrepresented by a hypergeometric test (Table 4). Importantly, the ChIP-Seq assays of the E2F1, c-Myc and Max transcription factors were performed on the HeLa-S3 cell line http://genome.ucsc.edu/. The fact that these experiments were performed in one of the cell lines we are investigating gives this bioinformatic analysis additional validity, because the cellular context is unlikely to be significantly different.
Table 4

Significantly overrepresented transcription factors identified by ENCODE ChIP-Seq peaks based on the GENCODE Database

Transcription Factor

cell line

tissue of origin

peaks near TSS of the gene of the extended network

peaks near TSS of all the

GENCODE genes

p-value

E2F1

HeLa-S3

cervical

187

1445

4.81E-013

TCF4

HCT-116

colorectal

244

2059

1.46E-012

Pol2

HeLa-S3

cervical

312

2878

3.93E-011

c-Myc

HeLa-S3

cervical

123

880

5.52E-011

Max

HeLa-S3

cervical

161

1266

9.77E-011

E2F6

k562

Leukemia

265

2379

1.17E-010

NFKB

GM12878

Lymphoblastoid

111

794

5.02E-010

The peaks were mapped to regions corresponding to the promoter sequences as considered for this study (-700, 300 bp), based upon transcription start sites (TSS) annotated by GENCODE. Peaks near TSS of the genes of the extended network and all GENCODE genes refers to the amount of peaks found in the promoter region. P-values were calculated by a hypergeometric test. Sample size was considered as the amount of genes that corresponded to the proteins of the extended network. Population size was the number of annotated GENCODE entries that had a complete status and were separated by a distance of up to 500 base pairs.

Also, it is noteworthy to mention that we performed a similar analysis, but using the promoter regions as reported in the Transcriptional Regulatory Element Database (TRED] [38] and employing the SwitchGear Database for the acquisition of the transcription start sites. Using this approach, we obtained a similar enrichment (Table 5).
Table 5

Significantly overrepresented transcription factors identified by ENCODE ChIP-Seq peaks based on the TRED Database

Transcription Factor

cell line

tissue of origin

peaks near TSS of the genes of the extended network

peaks near TSS reported on SwitchGear

p-value

Pol2

HeLa-S3

cervical

608

7766

2.15E-067

TCF4

HCT-116

colorectal

455

5543

1.93E-050

E2F6

k562

Leukemia

488

6343

1.12E-046

Max

HeLa-S3

cervical

313

3375

2.90E-042

c-Myc

HeLa-S3

cervical

250

2395

1.88E-041

NFKB

GM12878

Lymphoblastoid

195

1802

6.78E-034

E2F1-HA

HeLa-S3

cervical

315

4272

7.57E-024

ChIP-Seq peaks mapped to regions corresponding to the promoter sequences as considered for this study (-700, 300 bp), based upon transcription start sites (TSS) annotated by SwitchGear. Peaks near TSS of the genes of the extended network and reported on SwitchGear refers to the amount of peaks found in the corresponding promoter regions. P-values were calculated by a hypergeometric test. Sample size was considered as the amount of genes that corresponded to the proteins of the extended network. Population size was the number of reported TSS reported on SwitchGear with a score greater than 20.

Among the overrepresented TFs, we consider that the presence of c-Myc is remarkable because it is in agreement to what is currently known about cancer cells in general. Also, c-Myc's primary binding partner for gene activation is Max, so that the presence of this protein is complementary to c-Myc's activity. The mechanisms that make of c-Myc a very powerful oncogene are not very clear; however, there is evidence that indicates that the activation of c-Myc correlates with approximately 70% of human cancers [39].

The first possible explanation for c-Myc's prevalence in cancer is that the genes it induces represent the primary response of nearly all signal transduction pathways known to be involved in cancer [39]. Likewise, Nilsson et al, [39] have suggested that a loss in c-Myc's ability to induce apoptosis can convert c-Myc into a pure promoter of cell growth and transformation. Concordantly, the abrogation of p53 function, which is the protein responsible for executing c-Myc's apoptotic response, has been substantiated in all HPV positive cell lines, as well as the HPV negative cell line, C33-A [40].

The last factor, E2F1, controls cell-cycle progression and DNA replication and it has been shown to be induced by c-Myc's activity [41]. E2F1 has also been implicated in c-Myc mediated down regulation of p27KIP1, which is a cyclin-dependent kinase inhibitor [42]. Finally, polymerase 2 featured as the DNA-binding protein with the most significant p-value, thereby providing us with a notion of the genes of the network that are being transcribed (Tables 4 and 5).

Discussion

We performed a comprehensive analysis that stems from data obtained by proteomic techniques, using perspectives of biological networks and the annotated data of the human genome and large-scale sequencing techniques available to the public as a tool for building models to infer biological behaviors (Figure 1).

As defined in this study, the "central core of cervical cancer" does not describe the immortalization process directly; rather, it represents processes involved in maintaining a viable and proliferating cell. Table 2 presents the biological processes that are enriched in our core set of proteins and as can be seen, these are suggestive of a malignant phenotype, where the main GOs are those related to UPR, metabolism, catabolic processes, maintenance of cell-location and cell death. These observations are consistent with our initial conjectures, since we considered that using the HaCaT cell line as a control would allow us to distinguish between immortalization and transformation, because HaCaT is an immortalized cell line with a stable kariotype and phenotype, which is non-tumorigenic.

One of the studies that uses the HaCaT cell line as a control was performed by Choi, et al.[14]. The main difference between the latter study and our work, is that they used cervix biopsies; this implies that there are important differences in the intracellular and extracellular contexts of the biological model. Likewise, even though the methodology they utilized only considers samples with the same pathologic diagnosis, it is likely that there is still an important amount of heterogeneity in their samples due to inter-individual differences. As expected, we only found one common protein among the results of both studies: Vimentin. However, they were able to identify a number of proteins that strengthen our findings such as Amy-1, which stimulates c-Myc's E-box dependent transactivation activity [43]; and Miz-1, which must be inhibited in order for c-Myc to mediate apoptosis [44]. Another result that supports our findings is that they observed a downregulation of 14-3-3σ, which plays an opposite role in cell growth, compared to 14-3-3ζ [45]. Finally, they also found a clear overexpression of chaperone proteins, different from the ones in our central core.

The acquisition of the reported interactions between the identified proteins provided a first insight of the key elements in the neoplastic dynamics, and became the meter that allowed us to judge the validity of later analysis, by seeking an overall agreement between the original and the extended network. It is noteworthy that for the small network the highest interconnected node was 14-3-3ζ, and this was not lost when we expanded the network. Also, both networks are enriched in similar processes.

When analyzing the extended network it is apparent that 6 of the members of the 14-3-3 protein family (ζ, γ, β, τ, σ and ε) feature among the highest interconnected nodes. This is consistent with the biological role of the members of this protein family as signal transduction molecules [46]. The identification of 14-3-3ζ and its role as a hub and as a bottleneck in the PPI network is particularly relevant because it is known to be involved in three important cellular processes: cell cycle regulation, signal transduction and regulation of apoptosis [4750].

Furthermore, we noticed that the 14-3-3ζ protein, which features as the highest interconnected node of both our networks, did not posses any ChIP-Seq peak near the transcription start site of its encoding gene. Upon more careful inspection throughout the entire length of the gene, we noticed that there appears to be a regulatory region inside the transcript. Importantly, we found binding sites of c-Myc, Max, E2F1 and Pol2 very close to each other. This has lead us to believe that one of the mechanisms that lead to 14-3-3ζ's overexpression is mediated by c-Myc and E2F1 (Figure 5).
https://static-content.springer.com/image/art%3A10.1186%2F1752-0509-5-96/MediaObjects/12918_2011_Article_714_Fig5_HTML.jpg
Figure 5

Model of Action of c-Myc, E2F1 and 14-3-3ζ. Model of the downstream events product of the overexpression and/or amplification of c-Myc, and its collaboration with the transcription factor E2F1. c-Myc promotes the expression of proteins that lead to survival and proliferation through processes such as metabolism, protein biosynthesis and transcription factors. Likewise, it enables the expression of proteins involved in epithelial mesenchymal transition. E2F1 and c-Myc work together to promote the expression of Cyclins and E2F factors that boost the transition between G1 and S phases of mitosis, as well as the expression of 14-3-3ζ and Bcl-2. Bcl-2 is an antiapoptotic protein that prevents the release of cytochrome c. The overexpression of 14-3-3ζ results in instability and degradation of p53, increased cell proliferation, and cytoplasmic sequestration of BAD with what brings drastic decrease of apoptosis.

It was previously reported by Jonsson and Bates [13] that cancer proteins exhibit a significantly different network topology when compared to proteins unrelated to cancer; as well as a higher ratio of promiscuous structural domains. This is in agreement with what is known about the members of the 14-3-3 protein family, which have been described as signal integrators, amplifying strong signals and filtering out weaker conflicting ones to achieve a meaningful, coordinate biological output, such as cell death or survival [51].

Also, there is strong evidence that the overexpression of 14-3-3ζ promotes p53 degradation by the proteosomal route [52], which is increased by the action of E6 in HPV-infected cells [7]. An enhanced turn-over rate of the p53 protein and the pleiotropic effects consequence of the increased number of 14-3-3ζ proteins, which are involved in a large number of cellular processes, could be the reason why not all infections develop into cancer and most of them are subclinical: c-Myc could be activating 14-3-3ζ in a differential manner. Therefore, we consider that we posses sufficient evidence to suggest the role of 14-3-3ζ in cervical cancer cell lines as the determining factor that can ultimately dictate the fate of a cell, regardless of it being infected with HPV; and cause it to undergo cell cycle deregulation onto malignant transformation (Figure 5).

Likewise, when we performed a biological pathway enrichment, which we consider the best way to perform a functional analysis, we found consistent results. To do this, we used the ConsensusPathDB site to find overrepresented KEGG pathways in the proteins of our extended network. The enrichment analysis showed an overrepresentation of survival factors of apoptosis pathways and focal adhesion that is related to invasion and metastasis, two of the most important and well-documented hallmarks of cancer; as well as various established cancer pathways like small cell lung cancer, prostate cancer, endometrial cancer and pathways in cancer (Table 3). This was obviously expected and helps to strengthen our analysis, indicating that the central core of cervical cancer, and its subsequent expansion proposed in the PPI interaction network, still retain those proteins that are closely related to the neoplastic process.

However, there are other pathways that do not present such a straightforward connection to cancer, such as the neurotrophin and T-cell receptor signaling pathways, bacterial infections and proteasome pathways. We can only speculate about their meaning, as the cellular stress, chronic inflammation, turnover of proteins, cell survival and evasion of the immune system are other features related to the progression and maintenance of tumorigenesis.

As a way to understand the underlying regulatory dynamics of the system, we also performed an enrichment analysis of transcription factor binding sites among the promoters of the genes of our extended network. We focused on the three transcription factors that complied with both of the following: those which were significantly overrepresented among the promoter regions of the genes of the proteins of our network and those in which the corresponding ChIP-Seq assays were carried out on the HeLa-S3 cell line http://genome.ucsc.edu/. The resulting transcription factors are: E2F1, c-Myc and Max. We believe that together, these transcription factors bring an overall feeling of coherence to the network because the overexpression of c-Myc is widespread in human cancers, and specifically in cervical cancer [53]. Moreover, there is evidence that E2F1 is activated by the E7 protein of HPV-16 in a pRB-independent manner [54], apart from its pRB-dependent activation, which in the case of HPV infected cells is also promoted by pRB inactivation by viral oncoprotein E7. In the context of cervical cancer, it has been reported that an overexpression of E2F1 can drive quiescent cells through G1 into S-phase of the cell cycle, ultimately leading to apoptosis or neoplastic transformation.

E2F1 has been shown to be an inhibitor of c-Myc's activator, β-catenin, by means of the Wnt pathway [55, 56]. We also found a clear overrepresentation of the TCF4 transcription factor in the genes of our network. This contradicts our previous finding because TCF4 functions in the activation of the Wnt pathway, and therefore, of c-Myc. However, we had to consider that all the published works that point to E2F1 as an inhibitor of c-Myc have been performed in colorectal cancer. Likewise, the evidence of enrichment of TCF4 binding sites was performed in the HCT-116 cell line and so we do not posses information about the function of this transcription factor in cervical cancer.

It has been observed in human foreskin keratinocyte and fibroblast (HFK and HFF) cells that the genetic background of the cell type can be determinant for the outcome of altered gene expression. This is the case of HFF which cannot be immortalized by the mere addition of oncoproteins E6 and E7, unlike the HFK cells, due to a differential turnover of c-Myc [57]. Moreover, as pointed by Bernards [58] in the context of colorectal cancer pRB is more likely to be acting as an oncoprotein than as a tumor suppressor, which is clearly not the case in cervical cancer. Considering all the previous evidence, we can only infer that the proteins pRB and E2F1 are acting with opposing roles in cervical cancer, as compared to colorectal cancer.

On the other hand, there are reports of E2F1 and c-Myc overexpression in cervical cancer, which also correlate their expression with advanced states of the disease [59]. Also, genetic studies of the E2F promoters have shown that these genes are induced by c-Myc, dependent on the E box sites. Coordinately, all data point to a model where c-Myc is activated by means different from the canonical pathways and is working with E2F1 to promote the neoplastic phenotype.

The possible scenario of molecular events in cervical cancer suggested by our study portrays the evasion of apoptosis mediated in two ways, first, the sequestration of the pro-apoptotic protein BAD by 14-3-3ζ [60] and the overexpression of the anti-apoptotic protein Bcl-2 managed by the interaction of c-Myc and E2F1 [61]. Evasion of apoptosis by these routes can be supported by the interaction of viral oncoproteins E6 and E7 with tumor suppressor proteins p53 and pRb, when there is persistent infection with high-risk HPV. Simultaneously, these oncoproteins are able to promote significant increase in proliferation, and immortalize cells through the activation of hTERT [62].

The expression of E2F factors and cyclins facilitated by c-Myc, together E2F1 leads to a quick transition from the G1 to the S phase of the cell cycle, and the consequent boost in growth and cell proliferation [63].

Finally, c-Myc overexpression allows a significant increase in cell proliferation by key roads, such as protein biosynthesis, central metabolism, the expression of transcription and cell cycle factors [64] and expression of 14-3-3ζ. All of these contribute to facilitate the transition from G1 to S phase [65]. c-Myc's mediated expression of Ezrin [66] also promotes epithelial mesenchyma transition, facilitated by the overexpression of vimentin [67] (Figure 5).

Conclusions

Our results suggest a phenotype shared by the six cervical cancer cell lines as a result of the overexpression of c-Myc, helped by E2F1, which in turn allows the overexpression of 14-3-3ζ and other proteins of the "central core of cervical cancer". This signal transduction protein has been reported in other models of cancer as being responsible for malignant transformation and the decision between life and death of cells (Figure 5).

Methods

Cell culture

The CaSki, HeLa, SiHa, C-33A, ViBo and CaLo cell lines were provided by the oncology laboratory of the Centro Medico Siglo XXI which belongs to the Instituto Mexicano del Seguro Social. The HaCaT cell line was donated by the Centro de Investigación Sobre Enfermedades Infecciosas, which belongs to the Instituto Nacional de Salud Pública. All cell lines were cultured in RPMI-advanced 1640 serum-free media (Gibco BRL, USA) with red phenol and antibiotic-antimycotic solution (10,000 units penicillin, 10 mg streptomycin, and 25 μg amphotericin B per mL), supplemented with 1% fetal bovine serum (Invitrogen, Carlsbad, CA) and 200 mM of GlutaMAX (Invitrogen). The cells were incubated in 5% of CO2 and humidity saturation at 37°C in culture flasks of 75 cm2 (Nalge Nunc International, Rochester, NY). Cells were harvested at 70% confluence with Verseno solution (Tris base 25 mM, NaCL 136.8 mM, KCl 5.36 mM, EDTA 1 mM pH7.7) and washed 3 times in phosphate buffer saline (0.1 M sodium phosphate and 0.15 M NaCl in one liter, pH 7.2).

Proteomic Analysis

Protein extraction and two dimensional gel electrophoresis were done as previously described [68]. Gels were dyed in colloidal coomasie [69] and scanned in a GS-800 densitometer (Bio-Rad, Hercules, CA). Digital images were analyzed and compared using the PDQuest 8.0.1 software (Bio-Rad). Each experiment was done in triplicate. Once the digital image of each gel was compared against the rest, the electrophoretic entities of interest were cut, alkylated, reduced, digested and automatically transferred to a MALDI analysis target by a Proteineer SP II and SP robot using the SPcontrol 3.1.48.0 v software (Bruker Daltonics, Bremen, Germany), with the aid of a DP Chemicals 96 gel digestion kit (Bruker Daltonics) and processed in a MALDI-TOF Autoflex (Bruker Daltonics) to obtain a mass fingerprint. We performed 100 satisfactory shots in 20 shotsteps, the peak resolution threshold was set at 1,500, the signal/noise ratio of tolerance was 6, and contaminants were not excluded. The spectrum was annotated by the flexAnalysis 1.2 v SD1 Patch 2 (Bruker Daltonics). The search engine MASCOT [70] was used to compare the fingerprints against the UNIPROT [71] release 2010_09 database with the following parameters: Taxon-Human, mass tolerance of up to 500 ppm, one miss-cleavage allowed, and as the fixed modification Carbamidomethyl and oxidation of methionine as the variable modification.

Western blot analysis

Antibodies for immunoblotting were as follows: anti-14-3-3ζ human polyclonal (Imgenex, San Diego, CA) and anti-α-tubulin mouse monoclonal (Zymed Laboratories, South San Francisco. CA). Equal amounts of protein samples were subjected to SDS-PAGE, and transferred to a polyvinylidene difluoride membrane (Immobilon-P, Millipore Corp., Billerica, MA, USA). After blocking with 5% skimmed milk, the membrane was washed in TBS-tween 20%, and incubated with a primary antibody, followed by a AP-conjugated second antibody anti-rabitt or anti-mouse (Zymed). Blots were detected by chromogenic substrate BCIP/NBT (Zymed).

Network Reconstruction

The network reconstruction was performed with the aid of the Cytoscape [72] Plugin, BisoGenet [73], using the identified proteins as bait nodes and adding edges with the following parameters: Organism> Homo sapiens, protein identifiers only; Data Settings>protein-protein interactions; all data sources and all experimental methods; method> By adding edges connecting input nodes and as Output> Proteins.

Network Extension

The primary network was extended by performing the bioinformatic bait technique, using the Cytoscape Plugin Bisogenet with the expand network option and the previous parameters, except that the method used was By adding neighbors of input nodes to a distance of one. The resulting network was subjected to a centrality measure analysis with the Plugin CentiScaPe1.1 [74].

Pathway and GO enrichment analysis

We performed an enrichment analysis of pathway-based sets of proteins considering all the nodes of our extended network. Enrichment was done employing ConsensusPathDB [75], of the Max Planck Institute for Molecular Genetics, by using the overrepresentation analysis online tool. As input, we uploaded the UNIPROT protein identifiers of all the elements of the extended network. We searched against pathways as defined by KEGG [76], with a minimal overlap with the input list of 5 and a p-value cutoff of 0.0001.

Also, employing the same website and the same analysis tool, we performed an enrichment analysis based on Gene Ontology [77] level 3 category of biological processes. For this analysis, we considered only the identified core proteins and set the p-value cutoff on 0.00001.

Promoter Analysis

To help us uncover some of the regulatory dynamics underlying cervical cancer we downloaded the Gencode Genes-ENCODE Gencode Gene Annotations table (wgEncodeGencodeManual V3) [78, 79] from the University of California Santa Cruz Genome Browser website [80]. From this table we retrieved the transcription start site of all GENCODE genes with a score greater than 750, as well as its associated ENSEMBL Transcript ID and gene name. Because some transcripts present several nearby start sites, we also set a filter that only considers start sites located at a distance greater than 500 bp, this reduced the amount of entries considered to 18,534. Promoter sequences were defined as 700 bp upstream and 300 bp downstream of the transcription start site. The promoter locations corresponding to the genes of the proteins of our network were identified based on the ENSEMBL transcript ID as well as the gene names and synonyms stated in the UNIPROT data of those proteins.

Peak information was downloaded from the Yale transcription factor binding site (TFBS) track of the ENCODE Project [80] with a preference for the assays from the HeLa-S3 cell line. A peak was considered to be inside the promoter if the mid-point of the peak was inside the 1,000 bp reported as the promoter sequence. Hypergeometric tests were performed in order to assess the significance of our findings. Sample size was considered as the number of promoters that contain TFBS. All methodology is summarized in Figure 1.

The data associated with this manuscript may be downloaded from ProteomeCommons.org Tranche using the following hash:

ixDTEeYyZfAfXrh8HgM4rHTY0BDvNFtaU/GHBpQW/ldOSRKlStNTsd5aKw9dla

58 iAmEm8L7H8jAZ7A+TR2SNpTg+EUAAAAAAAAB8Q==

Notes

Abbreviations

ChIP: 

Chromatin immunoprecipitation

GO: 

Gene Ontology

HPV: 

Human Papillomavirus

HR-HPV: 

High Risk Human Papillomavirus

HFF: 

Human foreskin fibroblast

HFK: 

Human foreskin keratinocyte

PCa: 

Prostate cancer

PPI: 

Protein-protein interaction

TF: 

Transcription factor

TFBS: 

Transcription factor binding site

UPR: 

Unfolded protein response

OD: 

Optical Density

EMT: 

Epithelial Mesenchymal Transition

KEGG: 

Kyoto Encyclopedia of Genes and Genomes

UniProt: 

Universal Protein Resource

ENCODE: 

Encyclopedia Of DNA Elements

ConsensusPathDB: 

ConsensusPath Database

EBI: 

European Bioinformatics Institute

EMBL: 

European Molecular Biology Laboratory.

Declarations

Acknowledgements

We would like to thank Mauricio Salcedo-Vargas to provide the cervical cancer cell lines, Gabriel Martínez-Batallar for his advice in PDQuest handling, Alberto Checa-Rojas for his help with cell culture, and Alberto Ramírez-Torres during the elaboration of 2D SDS-PAGE.

Part of this work was supported by CONACyT grant 152167 and DGAPA-PAPIIT grant IN-216260. Juan Carlos Higareda-Almaraz is a recipient of a PhD Studentship from the CONACyT, CVU 176426.

Authors’ Affiliations

(1)
Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México
(2)
Licenciatura en Ciencias Genómicas, Universidad Nacional Autónoma de México

References

  1. Kreeger PK, Lauffenburger DA: Cancer systems biology: a network modeling perspective. Carcinogenesis. 2010, 31: 2-8. 10.1093/carcin/bgp261PubMed CentralView ArticlePubMedGoogle Scholar
  2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9View ArticlePubMedGoogle Scholar
  3. Hanahan D, Weinberg RA: Hallmarks of cancer: The Next Generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013View ArticlePubMedGoogle Scholar
  4. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348: 518-527. 10.1056/NEJMoa021641View ArticlePubMedGoogle Scholar
  5. von Knebel Doeberitz M, Rittmüller C, zur Hausen H, Dürst M: Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer. 1992, 51: 831-834. 10.1002/ijc.2910510527View ArticlePubMedGoogle Scholar
  6. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990, 63: 1129-1136. 10.1016/0092-8674(90)90409-8View ArticlePubMedGoogle Scholar
  7. Boyer SN, Wazer DE, Band V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996, 56: 4620-4624.PubMedGoogle Scholar
  8. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010, 401: 70-79. 10.1016/j.virol.2010.02.002PubMed CentralView ArticlePubMedGoogle Scholar
  9. Masters JR: HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer. 2002, 2: 315-319. 10.1038/nrc775View ArticlePubMedGoogle Scholar
  10. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE: Cervical cancer prevention: new tools and old barriers. Cancer. 2010, 116: 2531-2542.PubMed CentralPubMedGoogle Scholar
  11. Molano M, Van Den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Muñoz N, Franceschi S: Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003, 158: 486-494. 10.1093/aje/kwg171View ArticlePubMedGoogle Scholar
  12. Perez-Plasencia C, Dueñas-Gonzalez A, Alatorre-Tavera B: Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway. Int Arch Med. 2008, 1: 10-18. 10.1186/1755-7682-1-10PubMed CentralView ArticlePubMedGoogle Scholar
  13. Jonsson PF, Bates PA: Global topological features of cancer proteins in the human interactome. Bioinformatics. 2006, 22: 2291-2297. 10.1093/bioinformatics/btl390PubMed CentralView ArticlePubMedGoogle Scholar
  14. Choi YP, Kang S, Hong S, Xie X, Cho NH: Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics. 2005, 5: 1481-1493. 10.1002/pmic.200401021View ArticlePubMedGoogle Scholar
  15. Camon E, Magrane M, Barrell D, Lee V, Dimmer E, Maslen J, Binns D, Harte N, Lopez R, Apweiler R: The Gene Ontology Annotation (GOA) Database: sharing knowledge in Uniprot with Gene Ontology. Nucl Acids Res. 2004, 32: D262-D266. 10.1093/nar/gkh021PubMed CentralView ArticlePubMedGoogle Scholar
  16. Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS: Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008, 105: 370-380. 10.1002/jcb.21835PubMed CentralView ArticlePubMedGoogle Scholar
  17. Goplen D, Wang J, Enger PØ, Tysnes BB, Terzis AJ, Laerum OD, Bjerkvig R: Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006, 66: 9895-9902. 10.1158/0008-5472.CAN-05-4589View ArticlePubMedGoogle Scholar
  18. Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P, Zhu T, Song A, Zhao L, Han Z, Chen G, Wang S, Meng L, Zhou J, Lu Y, Wang S, Ma D: Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 2008, 28: 327-334.PubMedGoogle Scholar
  19. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M: The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005, 7: R365-R373. 10.1186/bcr1006PubMed CentralView ArticlePubMedGoogle Scholar
  20. Mierke CT, Kollmannsberger P, Zitterbart DP, Diez G, Koch TM, Marg S, Ziegler WH, Goldmann WH, Fabry B: Vinculin facilitates cell invasion into three-dimensional collagen matrices. J Biol Chem. 2010, 285: 13121-13130. 10.1074/jbc.M109.087171PubMed CentralView ArticlePubMedGoogle Scholar
  21. Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, Mao C, Ye R, Wang M, Pen L, Dubeau L, Groshen S, Hofman FM, Lee AS: Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008, 68: 498-505. 10.1158/0008-5472.CAN-07-2950View ArticlePubMedGoogle Scholar
  22. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS: Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003, 278: 20915-20924. 10.1074/jbc.M212328200View ArticlePubMedGoogle Scholar
  23. Warburg O: On the Origin of Cancer Cells. Science. 1956, 123: 309-314. 10.1126/science.123.3191.309View ArticlePubMedGoogle Scholar
  24. Ferguson EC, Rathmell JC: New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem Sci. 2008, 33: 359-362. 10.1016/j.tibs.2008.05.006PubMed CentralView ArticlePubMedGoogle Scholar
  25. Resendis-Antonio O, Checa A, Encarnación S: Modeling core metabolism in cancer cells: surveying the topology underlying the warburg effect. PloS one. 2010, 5: e12383- 10.1371/journal.pone.0012383PubMed CentralView ArticlePubMedGoogle Scholar
  26. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324: 1029-1033. 10.1126/science.1160809PubMed CentralView ArticlePubMedGoogle Scholar
  27. Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, Griffioen AW: Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010, 70: 6216-6224. 10.1158/0008-5472.CAN-09-4150View ArticlePubMedGoogle Scholar
  28. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, Hong SC, Choi SK, Ha WS, Kim JW, Lee JS, Park ST: Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer. 2007, 120: 2331-2338. 10.1002/ijc.22434View ArticlePubMedGoogle Scholar
  29. Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, Derow C, Dimmer E, Feuermann M, Friedrichsen A, Huntley R, Kohler C, Khadake J, Leroy C, Liban A, Lieftink C, Montecchi-Palazzi L, Orchard S, Risse J, Robbe K, Roechert B, Thorneycroft D, Zhang Y, Apweiler R, Hermjakob H: IntAct--open source resource for molecular interaction data. Nucl Acids Res. 2007, 35: D561-D565. 10.1093/nar/gkl958PubMed CentralView ArticlePubMedGoogle Scholar
  30. Stark C, Breitkreutz B, Reguly T, Boucher L, Breitkreutz A, Tyers M: BioGRID: a general repository for interaction datasets. Nucl Acids Res. 2006, 34: D535-D539. 10.1093/nar/gkj109PubMed CentralView ArticlePubMedGoogle Scholar
  31. Ceol A, Aryamontri CA, Licata L, Peluso D, Briganti L, Perfetto L, Castagnoli L, Cesareni G: MINT, the molecular interaction database: 2009 update. Nucl Acids Res. 2010, 38: D532-D539. 10.1093/nar/gkp983PubMed CentralView ArticlePubMedGoogle Scholar
  32. Xenarios I, Salwínski L, Duan XJ, Higney P, Kim S, Eisenberg D: DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions. Nucl Acids Res. 2002, 30: 303-305. 10.1093/nar/30.1.303PubMed CentralView ArticlePubMedGoogle Scholar
  33. Bader GD, Betel D, Hogue CW: BIND: the Biomolecular Interaction Network Database. Nucl Acids Res. 2003, 31: 248-250. 10.1093/nar/gkg056PubMed CentralView ArticlePubMedGoogle Scholar
  34. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, Chandrika KN, Deshpande N, Suresh S, Rashmi BP, Shanker K, Padma N, Niranjan V, Harsha HC, Talreja N, Vrushabendra BM, Ramya MA, Yatish AJ, Joy M, Shivashankar HN, Kavitha MP, Menezes M, Choudhury DR, Ghosh N, Saravana R, Chandran S, Mohan S, Jonnalagadda CK, Prasad CK, Kumar-Sinha C, Deshpande KS, Pandey A: Human protein reference database as a discovery resource for proteomics. Nucl Acids Res. 2004, 32: D497-D501. 10.1093/nar/gkh070PubMed CentralView ArticlePubMedGoogle Scholar
  35. Joy MP, Brock A, Ingber DE, Huang S: High-betweenness proteins in the yeast protein interaction network. J Biomed Biotechnol. 2005, 2: 96-103.View ArticleGoogle Scholar
  36. Hao P, Zheng S, Ping J, Tu K, Gieger C, Wang-Sattler R, Zhong Y, Li Y: Human gene expression sensitivity according to large scale meta-analysis. BMC Bioinformatics. 2009, 10 (Suppl 1): S56-S63. 10.1186/1471-2105-10-S1-S56PubMed CentralView ArticlePubMedGoogle Scholar
  37. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, Euskirchen G, Bernier B, Varhol R, Delaney A, Thiessen N, Griffith OL, He A, Marra M, Snyder M, Jones S: Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat Methods. 2007, 4: 651-657. 10.1038/nmeth1068View ArticlePubMedGoogle Scholar
  38. Jiang C, Xuan Z, Zhao F, Zhang MQ: TRED: a transcriptional regulatory element database, new entries and other development. Nucl Acids Res. 2007, 35: D137-D140. 10.1093/nar/gkl1041PubMed CentralView ArticlePubMedGoogle Scholar
  39. Nilsson JA, Cleveland JL: Myc pathways provoking cell suicide and cancer. Oncogene. 2003, 22: 9007-9021. 10.1038/sj.onc.1207261View ArticlePubMedGoogle Scholar
  40. Scheffner M, Münger K, Byrne JC, Howley PM: The State of the p53 and Retinoblastoma Genes in Human Cervical Carcinoma Cell Lines. Proc Natl Acad Sci USA. 1991, 88: 5523-5527. 10.1073/pnas.88.13.5523PubMed CentralView ArticlePubMedGoogle Scholar
  41. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, Ooi HS, Orlov YL, Shahab A, Yong HC, Fu Y, Weng Z, Kuznetsov VA, Sung WK, Ruan Y, Dang CV, Wei CL: Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA. 2006, 103: 17834-17839. 10.1073/pnas.0604129103PubMed CentralView ArticlePubMedGoogle Scholar
  42. Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF, Cleveland JL: Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. Mol Cells. 2003, 11: 905-914. 10.1016/S1097-2765(03)00102-3.View ArticleGoogle Scholar
  43. Sakamuro D, Prendergast GC: New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999, 18: 2942-2954. 10.1038/sj.onc.1202725View ArticlePubMedGoogle Scholar
  44. Patel JH, McMahon SB: Targeting of Miz-1 Is Essential for Myc-mediated Apoptosis. J Biol Chem. 2006, 281: 3283-3289.View ArticlePubMedGoogle Scholar
  45. Hong HY, Jeon WK, Bae EJ, Kim ST, Lee HJ, Kim SJ, Kim BC: 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-beta 1. Mol Cells. 2010, 29: 305-309. 10.1007/s10059-010-0037-8View ArticlePubMedGoogle Scholar
  46. Tzivion G, Shen YH, Zhu J: 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene. 2001, 20: 6331-6338. 10.1038/sj.onc.1204777View ArticlePubMedGoogle Scholar
  47. Morrison DK: The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 2009, 19: 16-23. 10.1016/j.tcb.2008.10.003PubMed CentralView ArticlePubMedGoogle Scholar
  48. Zhang P, Chan SL, Fu W, Mendoza M, Mattson MP: TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein-binding ability. FASEB J. 2003, 17: 767-779.PubMedGoogle Scholar
  49. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF: Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res. 2001, 56: 127-155. 10.1210/rp.56.1.127View ArticlePubMedGoogle Scholar
  50. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004, 116: 855-867. 10.1016/S0092-8674(04)00215-6View ArticlePubMedGoogle Scholar
  51. Niemantsverdriet M, Wagner K, Visser M, Backendorf C: Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene. 2008, 27: 1315-1319. 10.1038/sj.onc.1210742View ArticlePubMedGoogle Scholar
  52. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D: 14-3-3 Zeta Down-Regulates P53 in Mammary Epithelial Cells and Confers Luminal Filling. Cancer Res. 2008, 68: 1760-1767. 10.1158/0008-5472.CAN-07-3177View ArticlePubMedGoogle Scholar
  53. Sagawa Y, Nishi H, Isaka K, Fujito A, Takayama M: The correlation of TERT expression with c-myc expression in cervical cancer. Cancer Lett. 2001, 168: 45-50. 10.1016/S0304-3835(01)00501-8View ArticlePubMedGoogle Scholar
  54. Hwang SG, Lee D, Kim J, Seo T, Choe J: Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J Biol Chem. 2002, 277: 2923-2930. 10.1074/jbc.M109113200View ArticlePubMedGoogle Scholar
  55. Abramova MV, Zatulovskiy EA, Svetlikova SB, Pospelov VA: e2f1 Gene is a new member of Wnt/beta-catenin/Tcf-regulated genes. Biochem Biophys Res Commun. 2010, 391: 142-146. 10.1016/j.bbrc.2009.11.020View ArticlePubMedGoogle Scholar
  56. Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Näär AM, Dyson NJ: E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature. 2008, 455: 552-556. 10.1038/nature07310PubMed CentralView ArticlePubMedGoogle Scholar
  57. Liu X, Dakic A, Chen R, Disbrow GL, Zhang Y, Dai Y, Schlegel R: Cell-restricted immortalization by human papillomavirus correlates with telomerase activation and engagement of the hTERT promoter by Myc. J Virol. 2008, 82: 11568-11576. 10.1128/JVI.01318-08PubMed CentralView ArticlePubMedGoogle Scholar
  58. Bernards R: Cancer: Entangled pathways. Nature. 2008, 455: 479-480. 10.1038/455479aView ArticlePubMedGoogle Scholar
  59. Arvanitis DA, Spandidos DA: Deregulation of the G1/S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: a case control study. Oncol Rep. 2008, 20: 751-760.PubMedGoogle Scholar
  60. Yang H, Masters SC, Wang H, Fu H: The proapoptotic protein Bad binds the amphipathic groove of 14-3-3zeta. Biochim Biophys Acta. 2001, 1547: 313-319. 10.1016/S0167-4838(01)00202-3View ArticlePubMedGoogle Scholar
  61. Li Q, Dashwood WM, Zhong X, Nakagama H, Dashwood RH: Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving b-catenin, c-Myc and E2F1. Oncogene. 2007, 26: 6194-6202. 10.1038/sj.onc.1210438PubMed CentralView ArticlePubMedGoogle Scholar
  62. Moody CA, Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010, 10: 550-560. 10.1038/nrc2886View ArticlePubMedGoogle Scholar
  63. Leung JY, Ehmann GL, Giangrande PH, Nevins JR: A role for Myc in facilitating transcription activation by E2F1. Oncogene. 2008, 27: 4172-4179. 10.1038/onc.2008.55View ArticlePubMedGoogle Scholar
  64. Eilers M, Eisenman RN: Myc's broad reach. Genes Dev. 2008, 22: 2755-2766. 10.1101/gad.1712408PubMed CentralView ArticlePubMedGoogle Scholar
  65. Hong HY, Jeon WK, Bae EJ, Kim ST, Lee HJ, Kim SJ, Kim BC: 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-beta 1. Mol Cells. 2010, 29: 305-309. 10.1007/s10059-010-0037-8View ArticlePubMedGoogle Scholar
  66. Chuan YC, Iglesias-Gato D, Fernandez-Perez L, Cedazo-Minguez A, Pang ST, Norstedt G, Pousette A, Flores-Morales A: Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene. 2010, 29: 1531-1542. 10.1038/onc.2009.442View ArticlePubMedGoogle Scholar
  67. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, Yu D: 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 2009, 16: 195-207. 10.1016/j.ccr.2009.08.010PubMed CentralView ArticlePubMedGoogle Scholar
  68. Salazar E, Díaz-Mejía JJ, Moreno-Hagelsieb G, Martínez-Batallar G, Mora Y, Mora J, Encarnación S: Characterization of the NifA-RpoN Regulon in Rhizobium etli in Free Life and in Symbiosis with Phaseolus vulgaris. Appl Environ Microbiol. 2010, 76: 4510-4520. 10.1128/AEM.02007-09PubMed CentralView ArticlePubMedGoogle Scholar
  69. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, Orecchia P, Zardi L, Righetti PG: Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis. 2004, 25: 1327-1333. 10.1002/elps.200305844View ArticlePubMedGoogle Scholar
  70. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS: Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999, 20: 3551-3567. 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2View ArticlePubMedGoogle Scholar
  71. The UniProt Consortium : The universal protein resource (UniProt). Nucl Acids Res. 2008, 36: D190-D195. 10.1093/nar/gkn141PubMed CentralView ArticleGoogle Scholar
  72. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13: 2498-2504. 10.1101/gr.1239303PubMed CentralView ArticlePubMedGoogle Scholar
  73. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, Bringas R: BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics. 2010, 11: 91-100. 10.1186/1471-2105-11-91PubMed CentralView ArticlePubMedGoogle Scholar
  74. Scardoni G, Petterlini M, Laudanna C: Analyzing biological network parameters with CentiScaPe. Bioinformatics. 2009, 25: 2857-2859. 10.1093/bioinformatics/btp517PubMed CentralView ArticlePubMedGoogle Scholar
  75. Kamburov A, Wierling C, Lehrach H, Herwig R: ConsensusPathDB--a database for integrating human functional interaction networks. Nucl Acids Res. 2009, 37: D623-D628. 10.1093/nar/gkn698PubMed CentralView ArticlePubMedGoogle Scholar
  76. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. Nucl Acids Res. 2000, 28: 27-30. 10.1093/nar/28.1.27PubMed CentralView ArticlePubMedGoogle Scholar
  77. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. Nat Genet. 2000, 25: 25-29. 10.1038/75556PubMed CentralView ArticlePubMedGoogle Scholar
  78. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, Pohl A, Raney BJ, Wang T, Hinrichs AS, Zweig AS, Fujita PA, Learned K, Rhead B, Smith KE, Kuhn RM, Karolchik D, Haussler D, Kent WJ: ENCODE whole-genome data in the UCSC Genome Browser. Nucl Acids Res. 2010, 38: D620-D625. 10.1093/nar/gkp961PubMed CentralView ArticlePubMedGoogle Scholar
  79. Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR, Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR, Clawson H, Barber GP, Haussler D, Kent WJ: The UCSC Genome Browser database: update 2010. Nucl Acids Res. 2010, 38: D613-D619.PubMed CentralView ArticlePubMedGoogle Scholar
  80. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D: The Human Genome Browser at UCSC. Genome Res. 2002, 12: 996-1006.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Higareda-Almaraz et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.